Lymphoma, Primary Effusion - 7 Studies Found

Recruiting : Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma
: AIDS-Related Primary Effusion Lymphoma
: 2016-07-01
:
  • Genetic: Laboratory Biomarker Analysis

Completed : Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
: Lymphoma
: 2005-09-20
:
  • Biological: bevacizumab
  • Biological: filgra
Terminated : Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
:
  • Non-Hodgkin's Lymphoma
  • Burkitt Lymphoma
  • AIDS-Related Diffuse Large Cell Lymphoma
  • AIDS-Related Plasmablastic Lymphoma
  • : 2010-09-01
    :
    • Drug: Cyclophosphamide Given I
Recruiting : Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
:
  • AIDS-Related Burkitt Lymphoma
  • AIDS-Related Diffuse Large B-cell Lymphoma
  • Drug: Prednisone Given PO
Not yet recruiting : Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
:
  • Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
  • ALK-Positive Large B-Cell Lymphoma

    • : 2017-01-31
    :
    • Other: Laboratory Biomarker Analysis

NOT_YET_RECRUITING : Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma
:
: 2024-11-21
: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses